Publication: Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC)
dc.contributor.author | Puerta, JM | |
dc.contributor.author | Jiménez Velasco, A | |
dc.contributor.author | García, MJ | |
dc.contributor.author | Molina, JR | |
dc.contributor.author | Ruiz, C | |
dc.contributor.author | Ferrer, C | |
dc.contributor.author | Durán, MS | |
dc.contributor.author | Simón, I | |
dc.contributor.author | Clavero, E | |
dc.contributor.author | Avellaneda, MC | |
dc.contributor.author | Rosell, A | |
dc.contributor.author | Ballesteros, I | |
dc.contributor.author | Ramírez, S | |
dc.contributor.author | Portero, MA | |
dc.contributor.author | Ramírez, MJ | |
dc.contributor.author | Fernández, M | |
dc.contributor.author | Jiménez, M | |
dc.contributor.author | Fe, R | |
dc.contributor.author | Mulero, N | |
dc.contributor.author | López, P | |
dc.contributor.authoraffiliation | [Puerta,JM] Hematology, Complejo Hospitalario Universitario de Granada, Granada. [Jiménez Velasco,A; Ruiz,C] Hospital Regional Universitario Carlos Haya, Málaga. [García,MJ] Complejo Hospitalario Torrecardenas,Almeria. [Molina,JR] Hospital Reina Sofia, Cordoba. [Ferrer,C] Hospital Comarcal San Juan de la Cruz, Ubeda. [Durán,MS] Complejo Hospitalario de Jaen, Jaen. [Simón,I] Hospital Nuestra Senora de Valme, Sevilla. [Clavero,E] Hospital Comarcal Santa Ana, Motril. [Avellaneda,MC] Hospital Comarcal San Agustin, Linares. [Rosell,A] Hematology, Hospital Universitario Virgen de la Victoria, Malaga. [Ballesteros,I] Hospital Comarcal de la Axarquia, Velez-Malaga. [Ramírez,S] Hospital Juan Ramon Jimenez, Huelva. [Portero,MA] Hematology, Hospital Universitario Virgen de Macarena, Sevilla. [Ramírez,MJ] Hospital de Jerez de la Frontera, Jerez de la Frontera. [Fernández,M] Hospital Infanta Margarita, Cabra. [Jiménez,M] Hospital General de Riotinto, Riotinto. [Fe,R] Hospital Punta de Europa, Algeciras. [Mulero,N] Hospital de la Linea, La Linea de la Concepcion. [López,P] Complejo Hospitalario Universitario de Granada, Granada, Spain. | es |
dc.date.accessioned | 2016-10-03T12:13:25Z | |
dc.date.available | 2016-10-03T12:13:25Z | |
dc.date.issued | 2016-06 | |
dc.description.abstract | Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinib on ENESTnd and Dasision clinical trials. | es |
dc.description.version | No | es |
dc.identifier.citation | Puerta JM, Jiménez Velasco A, García MJ, Molina JR, Ruiz C, Ferrer C, et al.Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC). Haematologica. 2016; 101(s1).PB1820 | es |
dc.identifier.essn | 1592-8721 | |
dc.identifier.issn | 0390-6078 | |
dc.identifier.uri | http://hdl.handle.net/10668/2445 | |
dc.journal.title | Haematologica | |
dc.language.iso | en | |
dc.organization | AGS Campo de Gibraltar Oeste | |
dc.organization | AGS Este de Málaga-Axarquía | |
dc.organization | AGS Norte de Huelva | |
dc.organization | AGS Norte de Jaén | |
dc.organization | AGS Sur de Córdoba | |
dc.organization | AGS Sur de Granada | |
dc.organization | AGS Jerez, Costa Noroeste y Sierra de Cádiz | |
dc.publisher | Ferrata Storti Foundation | es |
dc.relation.publisherversion | http://www.haematologica.org/content/101/s1 | es |
dc.rights.accessRights | open access | |
dc.subject | Dasatinib | es |
dc.subject | Humanos | es |
dc.subject | Mesilato de imatinib | es |
dc.subject | Leucemia mielogenosa crónica BCR-ABL positiva | es |
dc.subject | Pirimidinas | es |
dc.subject | Sistema de registros | es |
dc.subject | Andalucía | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Thiazoles::Dasatinib | es |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate | es |
dc.subject.mesh | Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive | es |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines | es |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries | es |
dc.title | Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC) | es |
dc.type | conference presentation | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- PuertaJM_EfficacyAndSafety.pdf
- Size:
- 61.25 KB
- Format:
- Adobe Portable Document Format
- Description:
- Abstract